Hepatocellular carcinomar
Conditions
Interventions
Gold Standard:1 Pathological findings:needle biopsy or surgery.
2 Clinical diagnosis standard (Diagnosis and treatment of primary liver cancer 2017 China)
ultrasound:LOGIQ 
/C1-6/3-5HZ
Sponsors
The Affiliate First Hospital Jilin University
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Between September 2018 and September 2020, patients who are checked up newfound liver neoplasm by ultrasound and make further examination by contrast enhanced ultrasound; 2. Patients who are confirmed the pathological diagnosis by needle biopsy or surgery; 3. Patients who are confirmed the clinical diagnosis of hepatocellular carcinoma by at least the one of the CT or MRI and another relevant auxiliary examination.
Exclusion criteria
Exclusion criteria: 1. There were neither pathological fingdings nor enhanced CT/MRI results with patients; 2. The time interval is over 30 days between contrast enhanced ultrasound findings and enhanced CT/MRI results; 3. Patients who have the risk of allergic reactions with SonoVue; 4. A woman who is pregnant or lactating period; 5. Patients who have severe pulmonary arterial hypertension or unstable angina.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| characteristic of CEUS;SEN, SPE, ACC, AUC of ROC; | — |
Secondary
| Measure | Time frame |
|---|---|
| Characteristic of ultrasound; | — |
Countries
China
Contacts
Public ContactDezhiZhang
The Affiliate First Hospital Jilin University
Outcome results
None listed